Healthcare firm Micro Labs has unveiled a dextrose drug Hypotab to treat low blood sugar in diabetic patients. “Hypotab is meant for type two diabetes patients who suddenly face hypoglycaemia (low sugar) in the body and those who take insulin, which makes them prone to develop the symptom,” Micro Labs vice-president B.R. Srinath told reporters here at a preview of the drug. Priced economically, the carbohydrate drug, to be bought only on prescription by a qualified doctor, will restore normal blood glucose levels in diabetic patients soon after it is consumed. Hypotab is the first standardised therapy to treat low blood sugar and manufactured using the advanced technology of AbMax Biotechnology Co in China, as it offers 20 micron particle size for faster absorption in the body and gives quick relief,” said Srinath. The city-based pharma firm has invested Rs5.5 crore to set up the drug plant in Puducherry, with an installed capacity of one million tablets per month. The Rs1,646-crore company is targeting Rs4.2 crore revenue in this fiscal (2012-13) from Hypotab, Rs12 crore in next fiscal (2013-14) and Rs24 crore in 2014-15, as the market for treating low sugar remains untapped. From gulftoday
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delays

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor